About Providence Therapeutics
Providence Therapeutics is a company based in Calgary (Canada) founded in 2015 by Eric Marcusson and Brad Sorenson.. Providence Therapeutics has raised $10.44 million across 13 funding rounds from investors including Gates Foundation and NGen. Providence Therapeutics offers products and services including mRNA Medicines Platform, INTENT LNP Platform, Manufacturing Platform, and Pipeline in Oncology. Providence Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Moderna, C4 Therapeutics, Erasca and MiRagen, among others.
- Headquarter Calgary, Canada
- Founders Eric Marcusson, Brad Sorenson
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$10.44 M (USD)
in 13 rounds
-
Latest Funding Round
$711.63 K (USD), Series A
May 06, 2025
-
Investors
Gates Foundation
& 1 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Providence Therapeutics
Providence Therapeutics offers a comprehensive portfolio of products and services, including mRNA Medicines Platform, INTENT LNP Platform, Manufacturing Platform, and Pipeline in Oncology. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for rapid development of mRNA-based vaccines
LNP system for mRNA delivery in therapeutics
System for efficient mRNA therapeutics manufacturing
Pipeline focused on mRNA vaccines for cancer treatment
Unlock access to complete
Funding Insights of Providence Therapeutics
Providence Therapeutics has successfully raised a total of $10.44M across 13 strategic funding rounds. The most recent funding activity was a Series A round of $711.63 thousand completed in May 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 13
- Last Round Series A — $711,627
-
First Round
First Round
(03 Aug 2016)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2025 | Amount | Series A - Providence Therapeutics | Valuation |
investors |
|
| May, 2025 | Amount | Debt – Conventional - Providence Therapeutics | Valuation |
investors |
|
| Mar, 2025 | Amount | Series A - Providence Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Providence Therapeutics
Providence Therapeutics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Gates Foundation and NGen. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Charitable foundation investments on poverty reduction and healthcare
|
Founded Year | Domain | Location | |
|
Advanced manufacturing and technology are advanced by NGen foundation.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Providence Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Providence Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Providence Therapeutics Comparisons
Competitors of Providence Therapeutics
Providence Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Moderna, C4 Therapeutics, Erasca and MiRagen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Providence Therapeutics
Frequently Asked Questions about Providence Therapeutics
When was Providence Therapeutics founded?
Providence Therapeutics was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Where is Providence Therapeutics located?
Providence Therapeutics is headquartered in Calgary, Canada. It is registered at Calgary, Alberta, Canada.
Who is the current CEO of Providence Therapeutics?
Brad Sorenson is the current CEO of Providence Therapeutics. They have also founded this company.
Is Providence Therapeutics a funded company?
Providence Therapeutics is a funded company, having raised a total of $10.44M across 13 funding rounds to date. The company's 1st funding round was a Series A of $209.77K, raised on Aug 03, 2016.
What does Providence Therapeutics do?
Providence Therapeutics was established in 2015 in Calgary, Canada, within the biotechnology sector. mRNA-based therapeutics are focused on by the company for cancer and COVID-19 applications. Vaccines are tailored to individual patients using tumor-specific mutations, aiming to trigger immune responses. T-cell activation is promoted to target and eliminate cancer cells. Specific products, including PTX-COVID19-B and PTX-COVID19-LT, have been created for COVID-19 management.
Who are the top competitors of Providence Therapeutics?
Providence Therapeutics's top competitors include Moderna, Jazz Pharmaceuticals and C4 Therapeutics.
What products or services does Providence Therapeutics offer?
Providence Therapeutics offers mRNA Medicines Platform, INTENT LNP Platform, Manufacturing Platform, and Pipeline in Oncology.
Who are Providence Therapeutics's investors?
Providence Therapeutics has 2 investors. Key investors include Gates Foundation, and NGen.